TARS
TARS clinical trials: Tarsus Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Tarsus Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 13
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
TARS on the catalyst calendar · TARS registry changes
- Primary completion Jul 7, 2028Sponsor estimatePhase 2NCT07886268A Study to Evaluate the Efficacy and Safety of TP-06 for PCEDTarsus Pharmaceuticals, Inc. · Persistent Corneal Epithelial DefectRecruitingTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2027Sponsor estimatePhase 2NCT07562087A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick ExposureTarsus Pharmaceuticals, Inc. · Lyme DiseaseActive, not recruitingTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT07443202Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)Tarsus Pharmaceuticals, Inc. · Ocular RosaceaEnrolling by invitationTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 18, 2023ActualPhase 2NCT05454956Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGDTarsus Pharmaceuticals, Inc. · Meibomian Gland DysfunctionCompletedTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 27, 2025ActualPhase 4NCT06182358Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens WearersTarsus Pharmaceuticals, Inc. · Demodex BlepharitisCompletedTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 26, 2024ActualPhase 2NCT05387083A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05Tarsus Pharmaceuticals, Inc. · Healthy VolunteerCompletedTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 3, 2021ActualPhase 1NCT05138861A Six Week Pharmacokinetic Study of TP-03 in Healthy SubjectsTarsus Pharmaceuticals, Inc. · HealthyCompletedTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2024Sponsor estimatePhase 2NCT06054217Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With DemodexTarsus Pharmaceuticals, Inc. · Meibomian Gland DysfunctionUnknown statusTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 9, 2022ActualPhase 3NCT04784091Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex BlepharitisTarsus Pharmaceuticals, Inc. · BlepharitisCompletedTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 4, 2021ActualPhase 2/Phase 3NCT04475432Safety and Efficacy of TP-03 for the Treatment of Demodex BlepharitisTarsus Pharmaceuticals, Inc. · BlepharitisCompletedTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 13, 2023ActualPhase 2NCT05838170Study of TP-04 in Participants With Papulopustular RosaceaTarsus Pharmaceuticals, Inc. · Papulopustular RosaceaCompletedTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2023ActualPhase 1NCT05720364Study to Evaluate the Food Effect of TP-05 in Healthy ParticipantsTarsus Pharmaceuticals, Inc. · HealthyCompletedTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 25, 2022ActualPhase 1NCT05138796A Pharmacokinetic Study of TP-05 in Healthy SubjectsTarsus Pharmaceuticals, Inc. · HealthyCompletedTARSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner